January 20, 2017 4:15 PM ET


Company Overview of Theraclone Sciences, Inc.

Company Overview

Theraclone Sciences, Inc., a discovery-stage biotech company, develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. It provides In-Situ Therapeutic Antibody Rescue technology, which allows for the rapid testing of human antibodies to find those with exceptional biological functions and activities; and TCN-032, a recombinant human monoclonal antibody for the treatment of patients hospitalized with serious influenza. The company has antibody programs at preclinical and clinical development stage targeting serious medical conditions with a significant unmet medical need, including triple negative and endocrine treatment resistant HER-2 negative breast cancer...

1124 Columbia Street

Seattle Life Sciences Building

Suite 300

Seattle, WA 98104

United States

Founded in 2004





Key Executives for Theraclone Sciences, Inc.

Chief Executive Officer and Director
Age: 57
Founder and Member of Scientific Advisory Board
Chief Financial Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Theraclone Sciences, Inc. Key Developments

OncoResponse Will Use Theraclone's I-STAR Immune Repertoire Screening Technology

OncoResponse has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences, of Seattle, Washington. OncoResponse will use Theraclone's I-STAR immune repertoire screening technology to identify therapeutic antibodies against novel targets from immuno-oncology treated patients. I-STAR technology rapidly screens antibodies made by the human immune system to identify those with exceptional reactivity that may lead to cancer treatment development.

Theraclone Sciences, Inc. Presents at BioPharm America 2015, Sep-15-2015 04:00 PM

Theraclone Sciences, Inc. Presents at BioPharm America 2015, Sep-15-2015 04:00 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Clifford J. Stocks, Chief Executive Officer and Director.

Wellcome Trust Selects Theraclone Sciences, Inc.'s I-STAR™ Technology to Identify Therapeutic Antibodies Against Ebola Virus

Theraclone Sciences, Inc. announced that its I-STAR™ Technology chosen by Wellcome Trust to identify Therapeutic Antibodies against Ebola Virus. The company will identify potential therapeutic antibodies against the Ebola virus utilizing the Company’s powerful human memory B-cell interrogation platform. The I-STARTM technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BIO Ventures for Global Health was instrumental in forming a consortium of Ebola experts for the endeavor, and will collaborate with Theraclone on management of the project. To fund the initial screening and development efforts, Theraclone will receive up to $4.4 million in a Series C financing, which includes an investment from the Wellcome Trust along with existing investors.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Theraclone Sciences, Inc., please visit www.theraclone-sciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.